After Hours Summary: OLLI -5% following earnings, CNAT -33% after drug trial fails to meet primary endpointAfter Hours Gainers:
Companies trading higher in after hours in reaction to news: PRTK +3% (new drug applications for oral and intravenous omadacycline accepted for priority review by FDA), FB +2.7% (higher in extended trade after CEO Zuckerberg hosts call with media), SGMO +2.4% (after closing up 6% on the day), MRVL +2.4% and AVGO +1% (initiated with Buy ratings at UBS), CASI +2.3% (after Exec Chairman Wei-Wu He and founder of Emerging Technology Partners affirmed increased active stake of 10.4% following previously disclosed securities purchase agreement), AMD +1.8% (upgraded to Buy from Hold at Stifel and initiated with Neutral at UBS)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: OLLI -4.9%, NG -3.9%
Companies trading lower in after hours in reaction to news: CNAT -33.4% (reports top-line results from Ph 2b POLT-HCV-SVR clinical trial - did not meet its primary endpoint but biopsy-based proof of concept in liver fibrosis and cirrhosis supports further evaluation), CHEK -15.6% (files for $10 mln ordinary share offering), CPRX -6.8% (following today's 16% move higher), LFIN -6.1% (pulling back in after seeing notable move higher ahead of tonight's CEO appearance on Fast Money), NOG -4.2% (amended exchange agreement -- reduced minimum amount of equity raise to $140 mln while providing common stock in the equity raise be issued solely for cash), RPAI -1.7% (attributed to block trade pricing), MU -1.6% (Director Johnson disclosed the sale of 25000 shares valued at ~$1.26 mln; initiated with Sell rating at UBS), ICPT -0.6% (proposes $120 million offering and concurrent $92 million private placement of common stock; CEO and Board members indicated interest in participating in the offering; expects net sales of Ocaliva for the quarter to be slightly lower y/y), INTC -0.3% (downgraded to Hold from Buy at Stifel)